These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21992770)

  • 1. Do oral aluminium phosphate binders cause accumulation of aluminium to toxic levels?
    Pepper R; Campbell N; Yaqoob MM; Roberts NB; Fan SL
    BMC Nephrol; 2011 Oct; 12():55. PubMed ID: 21992770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
    Weinreich T; Ritz E; Passlick-Deetjen J
    Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma aluminium: a redundant test for patients on dialysis?
    Gault PM; Allen KR; Newton KE
    Ann Clin Biochem; 2005 Jan; 42(Pt 1):51-4. PubMed ID: 15802033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silicon and aluminium interactions in haemodialysis patients.
    Parry R; Plowman D; Delves HT; Roberts NB; Birchall JD; Bellia JP; Davenport A; Ahmad R; Fahal I; Altmann P
    Nephrol Dial Transplant; 1998 Jul; 13(7):1759-62. PubMed ID: 9681724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminum overload in the reverse osmosis dialysis era: does it exist?
    Chen MY; Ou SH; Chen NC; Yin CH; Chen CL
    Ren Fail; 2022 Dec; 44(1):1595-1603. PubMed ID: 36190833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
    Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
    Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
    Arenas MD; Malek T; Gil MT; Moledous A; Núñez C; Alvarez-Ude F
    Nefrologia; 2008; 28(2):168-73. PubMed ID: 18454706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative roles of intestinal absorption and dialysis-fluid-related exposure in the accumulation of aluminium in haemodialysis patients.
    Mazzaferro S; Perruzza I; Costantini S; Pasquali M; Onorato L; Sardella D; Giordano R; Ciaralli L; Ballanti P; Bonucci E; Cinotti GA; Coen G
    Nephrol Dial Transplant; 1997 Dec; 12(12):2679-82. PubMed ID: 9430871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of aluminium in patients with acute renal failure.
    Davenport A; Roberts NB
    Nephron; 1989; 52(3):253-8. PubMed ID: 2739864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the utility of testing aluminum levels in dialysis patients.
    Sharma AK; Toussaint ND; Pickering J; Beeston T; Smith ER; Holt SG
    Hemodial Int; 2015 Apr; 19(2):256-62. PubMed ID: 25306885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aluminium-induced bone disease in uremic rats: effect of deferoxamine.
    Jablonski G; Klem KH; Danielsen CC; Mosekilde L; Gordeladze JO
    Biosci Rep; 1996 Feb; 16(1):49-63. PubMed ID: 8861540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?
    Mudge DW; Johnson DW; Hawley CM; Campbell SB; Isbel NM; van Eps CL; Petrie JJ
    BMC Nephrol; 2011 May; 12():20. PubMed ID: 21569446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia.
    Hutchison AJ; Freemont AJ; Boulton HF; Gokal R
    Nephrol Dial Transplant; 1992; 7(12):1219-25. PubMed ID: 1337163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.